Table 5. Bevacizumab vs ranibizumab for PCV: 1-year result of treatment.
| Bevacizumab (66 eyes of 63 patients) | Ranibizumab (60 eyes of 58 patients) | P | |
|---|---|---|---|
| Mean logMAR | 0.76 | 0.74 | 0.82a |
| Mean logMAR change from baseline | −0.11 | −0.14 | 0.89a |
| BCVA changes | |||
| Gained ≥logMAR 0.3 | 18.2% | 23.3% | 0.65b |
| Loss ≥logMAR 0.3 | 19.7% | 20.0% | 0.85b |
| Mean FCT changes from baseline (μm) | −69 | −84 | 0.74a |
| FCT changes | |||
| Decreased by 10% or more | 43.4% | 51.2% | 0.34b |
| Increased by 10% or more | 13.8% | 12.2% | 0.91b |
| Polyp regression | |||
| Regression | 24.2% | 23.3% | 0.92b |
| Persistence | 75.8% | 76.7% | 0.88b |
Abbreviations: BCVA, best-corrected visual acuity; FCT, foveal center thickness; GLD, greatest linear dimension; ICGA, indocyanine green angiography, polypoidal choroidal vasculopathy; PCV, polypoidal choroidal vasculopathy.
a
On the basis of student t-test.
b
On the basis of χ2-test.